國家衛生研究院 NHRI:Item 3990099045/2727
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 912797      Online Users : 1166
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/2727


    Title: In vitro and in vivo studies of a novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells
    Authors: Chen, YL;Lin, SZ;Chang, JY;Cheng, YL;Tsai, NM;Chen, SP;Chang, WL;Harn, HJ
    Contributors: National Institute of Cancer Research
    Abstract: We previously demonstrated that the crude acetone extract of Bupleurum scorzonerifolium (BS-AE) 60 mu g/ml has anti-proliferation activity and apoptotic effects on A549 non-small cell lung cancer (NSCLC). A novel lignan, isochaihulactone (4-benzo[1,3]dioxol-5-yl1methyl-3 (3,4,5-trimethoxyl-benzylidene)-dihydro-furan-2-one), was isolated from BS-AE and identified from spectral evidence (H-1 NMR, C-13 NMR, IR, and MS) and by comparison with authentic synthetic standards. Isochaihulactone was cytotoxic (IC50 = 10-50 mu M) in a variety of human tumor cell lines. In in Vitro and in vivo microtubule assembly assays, it inhibited tubulin polymerization in a concentration-dependent manner. As determined by flow cytometry, isochaihulactone caused G2/M phase arrest and apoptosis in a time- and concentration-dependent manner. G2/M arrest was correlated with increased p21/WAF1 levels, downregulation of the checkpoint proteins cyclin B1/cdc2 and mobility shift of cdc25G. Moreover, isochaihulactone (30 and 50 mg/kg) inhibited the growth of non-small cell lung carcinoma A549 xenograft in nude mice. These findings indicate isochaihulactone is. a promising new antimitotic anticancer compound with potential for clinical application in the future. (c) 2006 Elsevier Inc. All rights reserved.
    Keywords: Pharmacology & Pharmacy
    Date: 2006-07-28
    Relation: Biochemical Pharmacology. 2006 Jul;72(3):308-319.
    Link to: http://dx.doi.org/10.1016/j.bcp.2006.04.031
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0006-2952&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000239235000004
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33745649582
    Appears in Collections:[Jang-Yang Chang] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    000239235000004.pdf800KbAdobe PDF624View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback